Stage 4 kidney cancer is not considered curable in most cases, but a meaningful number of people live years or even decades after diagnosis. The overall 5-year survival rate for kidney cancer that has spread to distant organs is about 19%, based on data from people diagnosed between 2015 and 2021. That number, though, masks a wide range of outcomes. Some patients with limited spread who respond well to modern treatments achieve “no evidence of disease” status and remain there for years. Others face a much harder path. Where you fall depends on several specific, measurable factors.
What “Stage 4” Actually Means
Stage 4 kidney cancer, most commonly renal cell carcinoma, means the cancer has either grown into tissue well beyond the kidney or spread to other parts of the body. The most frequent sites of metastasis are the lungs, liver, bone, and lymph nodes. Less commonly, it reaches the brain or adrenal glands. The number and location of those metastases play a large role in determining treatment options and likely outcomes.
A person with a single lung nodule faces a very different situation than someone with cancer in the bones, liver, and brain simultaneously. Bone metastases in particular have been linked to worse outcomes compared to spread limited to the lungs or lymph nodes.
Why Doctors Avoid the Word “Cured”
In oncology, “remission” and “no evidence of disease” (NED) both mean that no cancer is currently detectable on scans, bloodwork, or biopsies. But neither term equals “cured.” Kidney cancer is known for late recurrences: in about 10% of patients, the cancer comes back more than a decade after surgery. Because of this unpredictability, doctors rarely declare someone with stage 4 disease cured outright. Instead, after enough time passes without relapse, patients transition from active surveillance into survivorship, with fewer and less frequent check-ups. There is no official milestone, such as 5 or 10 years, that automatically changes a patient’s status.
How Risk Categories Shape Survival
Not all stage 4 kidney cancer carries the same prognosis. Oncologists use scoring systems that weigh factors like overall health, blood markers, and how quickly the disease progressed to sort patients into risk groups: favorable (good), intermediate, and poor. These categories matter because they predict how long treatment is likely to work and guide which therapy to use.
In one analysis of patients treated with modern immunotherapy, those in the good-risk group survived so long that the median survival was never reached during the study period, meaning more than half were still alive when follow-up ended. Intermediate-risk patients had a median survival of about 30 months. Poor-risk patients had a median of roughly 17 months, and those classified as very poor risk survived a median of just over 4 months. About 15% of metastatic kidney cancer patients fall into the favorable category, while roughly 55% are intermediate risk.
Modern Treatments That Changed the Outlook
The survival landscape for stage 4 kidney cancer shifted dramatically with the introduction of immunotherapy combinations. In the landmark CheckMate 214 trial, which combined two immunotherapy drugs, 48% of patients with intermediate or poor-risk disease were alive at 5 years, compared to 37% on the older standard treatment. That’s a substantial improvement over the single-digit survival rates common in the early 2000s.
Combinations pairing immunotherapy with targeted therapy have also shown strong results. In one study of such a combination, 73% of patients had their tumors shrink measurably, and the median time before the cancer progressed was nearly two years. Five patients in that trial achieved a complete response, meaning all detectable cancer disappeared, and all five were still alive at follow-up. Response rates were similar across risk groups: about 75% for favorable-risk patients and 69% for intermediate and poor-risk patients combined.
When Surgery Still Plays a Role
For select patients, surgery remains a powerful tool even at stage 4. Two types of operations come into play: removing the primary kidney tumor (cytoreductive nephrectomy) and removing individual metastases (metastasectomy).
Current guidelines recommend considering removal of the primary tumor for patients who are in good overall health, have few risk factors, and have limited metastatic spread. The timing matters, too. In a large study of over 1,500 patients, those who started systemic therapy first and then had kidney surgery after showing a response had significantly better survival than those who went straight to surgery. This “try treatment first, then operate” approach lets doctors identify which patients are most likely to benefit.
Outcomes for Limited Spread
Patients with oligometastatic disease, defined as three or fewer metastatic lesions, can sometimes have those lesions surgically removed. The results for this group are strikingly better than the overall stage 4 statistics. In a 10-year single-center study, patients who had metastases surgically removed had 5-year and 10-year survival rates of 83% and 80%, respectively. Patients treated with systemic therapy alone had 5-year and 10-year survival rates of 53% and 42%. This is as close to a “cure” as stage 4 kidney cancer gets, though ongoing surveillance remains necessary because of the risk of late recurrence.
One remarkable case report describes a patient who survived 20 years after initial surgery, undergoing sequential removal of more than 38 metastases over that period. While this is exceptional, it illustrates that stage 4 kidney cancer does not always follow a single, predictable trajectory.
What Determines Your Specific Outlook
Several factors tilt the odds in one direction or another. The ones that matter most include:
- Number and location of metastases: Fewer sites of spread and lung-only metastases generally carry a better prognosis than bone, liver, or brain involvement.
- Overall health and fitness: Patients well enough to be active and independent tolerate treatment better and live longer.
- Time from diagnosis to treatment: Cancers that spread quickly after the initial kidney cancer diagnosis tend to be more aggressive.
- Response to initial therapy: Tumors that shrink with the first round of treatment signal a biology more likely to be controlled long-term.
- Tumor type: Clear cell renal cell carcinoma, the most common subtype, generally responds better to current immunotherapy combinations than rarer subtypes.
The 19% five-year survival figure from national databases reflects all stage 4 patients, including those diagnosed years ago on older treatments and those too sick to receive aggressive therapy. For a patient in good health today, starting a modern immunotherapy combination and falling into a favorable or intermediate risk group, the realistic five-year survival probability is considerably higher than that headline number suggests.